Article

Huntington's Disease Can Affect the Heart

Author(s):

Huntington's Disease (HD) is an autosomal dominant progressive neurodegenerative disorder. In addition to the central nervous system disturbance the ailment causes, there is increasing evidence the genetic abnormality also affects peripheral organs and tissues.

Huntington’s Disease (HD) is an autosomal dominant progressive neurodegenerative disorder. In addition to the central nervous system disturbance the ailment causes, there is increasing evidence the genetic abnormality also affects peripheral organs and tissues.

In a study presented April 22 during a poster session at the 2015 annual meeting of the American Academy of Neurology, Christopher Stephen, MD, a neurologist at Massachusetts General Hospital in Boston, MA, and colleagues reported on electrocardiogram results in a sample of patients with Huntington’s Disease.

They found that 25.3 % of the 598 early HD patients, all over age 18, had abnormal electrocardiograms (ECGs).

Nearly all of the patients were in the first 2 stages of Huntington’s Disease.

After controlling for medications with cardiac effects and other relevant medical conditions, the team found 23.7% had marked bradycardia. Prolonged intraventricular condition was also significantly higher in these patients (4.3% in HD patients vs. 1.3% in non-HD populations.)

“The increased prevalence in conduction abnormalities and bradycardia in early Huntington’s Diseasesuggest possible compromise of the cardiac bundles and sinoatrial mode, which could lower the threshold for arrhythmia and aggravate cardiac failure,” Stephen concluded.

The results are important in part because they suggest physicians and researchers should use caution in prescribing medications or experimental therapies that may have cardiac toxicity.

Related Videos
Marcelo Kugelmas, MD | Credit: South Denver Gastroenterology
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
© 2024 MJH Life Sciences

All rights reserved.